Quest Diagnostics Incorporated (DGX) · Insider trading
What Quest Diagnostics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$37.27M
8 insiders, 97% under a plan
Net, 12 months
−$37.27M
bought less sold
Latest filing
2026-09-03
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Davis J. E.Director, CEO and President | – | $23.69M | 21 | 2026-09-01 | 122,423 |
| Prevoznik Michael eSVP & General Counsel | – | $18.84M | 16 | 2026-08-28 | 44,224 |
| Doherty Catherine T.EVP, Regional Businesses | – | $13.81M | 15 | 2026-03-05 | 67,122 |
| Kuppusamy KarthikSVP, Clinical Solutions | – | $4.64M | 7 | 2026-06-04 | 13,510 |
| Plewman PatrickSVP for Diagnostic Services | – | $4.60M | 10 | 2026-03-05 | 15,198 |
| Deppe Michael JSVP, Corp. Controller & CAO | – | $2.89M | 6 | 2024-11-06 | 51,596 |
| Delaney Mark eSVP & Chief Commercial Officer | – | $2.24M | 5 | 2026-07-28 | 10,335 |
| Gregg Vicky BDirector | – | $445,412 | 2 | 2025-11-25 | 17,037 |
| Pfeiffer Gary MDirector | – | $270,317 | 1 | 2025-10-22 | 29,431 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Davis J. E.Director, CEO and President | Saleplan | 10,000 | 242.72 | $2.43M | 122,423 | Form 4 |
| 2026-08-28 | Prevoznik Michael eSVP & General Counsel | Saleplan | 16,010 | 242.88 | $3.89M | 44,224 | Form 4 |
| 2026-08-28 | Prevoznik Michael eSVP & General Counsel | Saleplan | 6,237 | 243.63 | $1.52M | 37,987 | Form 4 |
| 2026-08-28 | Prevoznik Michael eSVP & General Counsel | Saleplan | 430 | 244.51 | $105,139 | 37,557 | Form 4 |
| 2026-07-28 | Delaney Mark eSVP & Chief Commercial Officer | Saleplan | 1,600 | 235.18 | $376,288 | 10,335 | Form 4 |
| 2026-06-04 | Kuppusamy KarthikSVP, Clinical Solutions | Saleplan | 8,147 | 200.00 | $1.63M | 13,510 | Form 4 |
| 2026-06-01 | Davis J. E.Director, CEO and President | Saleplan | 10,000 | 194.14 | $1.94M | 132,423 | Form 4 |
| 2026-03-05 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 2,855 | 206.21 | $588,730 | 15,198 | Form 4 |
| 2026-03-05 | Prevoznik Michael eSVP & General Counsel | Saleplan | 3,878 | 206.21 | $799,682 | 37,557 | Form 4 |
| 2026-03-05 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 5,558 | 206.21 | $1.15M | 67,122 | Form 4 |
| 2026-03-04 | Kuppusamy KarthikSVP, Clinical Solutions | Sale | 2,628 | 204.86 | $538,372 | 13,441 | Form 4 |
| 2026-03-03 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 410 | 207.73 | $85,169 | 15,198 | Form 4 |
| 2026-03-03 | Prevoznik Michael eSVP & General Counsel | Saleplan | 526 | 207.73 | $109,266 | 37,557 | Form 4 |
| 2026-03-03 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 632 | 207.73 | $131,285 | 67,122 | Form 4 |
| 2026-03-02 | Davis J. E.Director, CEO and President | Saleplan | 10,000 | 212.52 | $2.13M | 117,185 | Form 4 |
| 2026-02-19 | Prevoznik Michael eSVP & General Counsel | Saleplan | 1,111 | 204.83 | $227,566 | 38,371 | Form 4 |
| 2026-02-19 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 958 | 204.83 | $196,227 | 15,838 | Form 4 |
| 2026-02-19 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 1,433 | 204.83 | $293,521 | 68,402 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 10,573 | 205.21 | $2.17M | 83,660 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 10,122 | 206.37 | $2.09M | 73,538 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 3,500 | 207.08 | $724,780 | 70,038 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 1,619 | 208.21 | $337,092 | 68,419 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 351 | 209.10 | $73,394 | 68,068 | Form 4 |
| 2026-02-10 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 5,662 | 204.00 | $1.16M | 15,381 | Form 4 |
| 2025-11-25 | Gregg Vicky BDirector | Sale | 1,250 | 191.76 | $239,700 | 17,037 | Form 4 |
| 2025-11-25 | Davis J. E.Director, CEO and President | Saleplan | 9,342 | 191.59 | $1.79M | 166,231 | Form 4 |
| 2025-11-25 | Davis J. E.Director, CEO and President | Saleplan | 41,004 | 192.27 | $7.88M | 125,227 | Form 4 |
| 2025-11-25 | Davis J. E.Director, CEO and President | Saleplan | 4,747 | 192.97 | $916,029 | 120,480 | Form 4 |
| 2025-11-18 | Delaney Mark eSVP & Chief Commercial Officer | Saleplan | 7,946 | 187.35 | $1.49M | 7,530 | Form 4 |
| 2025-10-22 | Pfeiffer Gary MDirector | Sale | 1,482 | 182.40 | $270,317 | 29,431 | Form 4 |
| 2025-09-26 | Prevoznik Michael eSVP & General Counsel | Saleplan | 83 | 187.22 | $15,539 | 38,261 | Form 4 |
| 2025-09-26 | Prevoznik Michael eSVP & General Counsel | Saleplan | 144 | 188.66 | $27,167 | 38,117 | Form 4 |
| 2025-09-24 | Prevoznik Michael eSVP & General Counsel | Saleplan | 175 | 187.02 | $32,728 | 38,117 | Form 4 |
| 2025-09-23 | Prevoznik Michael eSVP & General Counsel | Saleplan | 28,288 | 187.12 | $5.29M | 38,117 | Form 4 |
| 2025-08-21 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 1,975 | 185.00 | $365,375 | 15,269 | Form 4 |
| 2025-08-19 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 4,532 | 183.00 | $829,356 | 17,244 | Form 4 |
| 2025-08-15 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 1,975 | 180.00 | $355,500 | 17,244 | Form 4 |
| 2025-08-06 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 3,560 | 175.00 | $623,000 | 21,185 | Form 4 |
| 2025-08-06 | Plewman PatrickSVP for Diagnostic Services | Saleplan | 1,975 | 175.00 | $345,625 | 19,219 | Form 4 |
| 2025-07-31 | Kuppusamy KarthikSVP, Clinical Solutions | Saleplan | 2,210 | 170.00 | $375,700 | 8,450 | Form 4 |
43 more
| 2025-07-30 | Kuppusamy KarthikSVP, Clinical Solutions | Saleplan | 3,045 | 167.40 | $509,733 | 10,660 | Form 4 |
| 2025-07-30 | Kuppusamy KarthikSVP, Clinical Solutions | Saleplan | 5,224 | 167.40 | $874,498 | 10,660 | Form 4 |
| 2025-05-13 | Delaney Mark eSVP & Chief Commercial Officer | Saleplan | 874 | 175.31 | $153,221 | 7,498 | Form 4 |
| 2025-05-12 | Delaney Mark eSVP & Chief Commercial Officer | Saleplan | 874 | 175.72 | $153,579 | 8,372 | Form 4 |
| 2025-04-02 | Kuppusamy KarthikSVP, Clinical Solutions | Saleplan | 2,555 | 170.00 | $434,350 | 10,575 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 2,366 | 168.03 | $397,559 | 164,448 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 1,411 | 168.76 | $238,120 | 163,037 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 704 | 169.63 | $119,420 | 162,333 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 7,249 | 167.86 | $1.22M | 155,084 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 4,905 | 168.72 | $827,572 | 150,179 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 2,764 | 169.56 | $468,664 | 147,415 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 6,950 | 167.86 | $1.17M | 140,465 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 5,900 | 168.66 | $995,094 | 134,565 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 2,493 | 169.57 | $422,738 | 132,072 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 750 | 167.86 | $125,895 | 131,322 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 584 | 168.70 | $98,521 | 130,738 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 267 | 169.60 | $45,283 | 130,471 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 1,493 | 167.88 | $250,645 | 128,978 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 902 | 168.79 | $152,249 | 128,076 | Form 4 |
| 2025-04-02 | Davis J. E.Director, CEO and President | Saleplan | 453 | 169.63 | $76,842 | 127,623 | Form 4 |
| 2025-03-17 | Prevoznik Michael eSVP & General Counsel | Saleplan | 4,643 | 170.00 | $789,310 | 38,117 | Form 4 |
| 2025-03-05 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 5,370 | 174.13 | $935,078 | 68,068 | Form 4 |
| 2025-03-04 | Prevoznik Michael eSVP & General Counsel | Saleplan | 592 | 175.79 | $104,068 | 38,117 | Form 4 |
| 2025-03-04 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 716 | 175.79 | $125,866 | 68,068 | Form 4 |
| 2025-02-27 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 824 | 172.61 | $142,231 | 69,178 | Form 4 |
| 2025-02-27 | Prevoznik Michael eSVP & General Counsel | Saleplan | 528 | 172.61 | $91,138 | 39,031 | Form 4 |
| 2025-02-20 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 899 | 170.99 | $153,720 | 70,457 | Form 4 |
| 2025-02-20 | Prevoznik Michael eSVP & General Counsel | Saleplan | 604 | 170.99 | $103,278 | 39,845 | Form 4 |
| 2025-02-19 | Doherty Catherine T.EVP, Regional Businesses | Saleplan | 535 | 169.71 | $90,795 | 71,356 | Form 4 |
| 2025-02-19 | Plewman PatrickSVP for Diagnostic Services | Sale | 320 | 169.71 | $54,307 | 18,082 | Form 4 |
| 2025-02-05 | Delaney Mark eSVP & Chief Commercial Officer | Sale | 403 | 164.30 | $66,213 | 4,624 | Form 4 |
| 2025-02-05 | Gregg Vicky BDirector | Sale | 1,250 | 164.57 | $205,712 | 16,867 | Form 4 |
| 2024-11-29 | Prevoznik Michael eSVP & General Counsel | Sale | 3,009 | 162.26 | $488,240 | 70,615 | Form 4 |
| 2024-11-29 | Prevoznik Michael eSVP & General Counsel | Sale | 32,137 | 163.15 | $5.24M | 38,478 | Form 4 |
| 2024-11-27 | Doherty Catherine T.EVP, Regional Businesses | Sale | 4,803 | 162.14 | $778,758 | 96,712 | Form 4 |
| 2024-11-27 | Doherty Catherine T.EVP, Regional Businesses | Sale | 28,300 | 163.13 | $4.62M | 68,412 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 2,100 | 152.70 | $320,670 | 51,596 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 2,400 | 153.98 | $369,552 | 49,196 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 4,135 | 154.74 | $639,850 | 45,061 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 2,600 | 152.71 | $397,046 | 42,461 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 2,331 | 154.03 | $359,044 | 40,130 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Sale | 5,189 | 154.74 | $802,946 | 34,941 | Form 4 |
| 2024-10-28 | Kuppusamy KarthikSVP, Clinical Solutions | Sale | 1,775 | 156.92 | $278,533 | 9,734 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
65 × grant or award64 × shares withheld for tax37 × small acquisition19 × option exercise1 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-28 | Prevoznik Michael eSVP & General Counsel | Option exercise M | +22,677 | 112.17 | 60,234 | Form 4 |
| 2026-08-28 | Prevoznik Michael eSVP & General Counsel | Gift G | −1,000 | – | 36,557 | Form 4 |
| 2026-07-22 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +34 | 206.81 | 11,935 | Form 4 |
| 2026-07-22 | Lassiter Wright IIIDirector | Small acquisition L | +6 | 206.81 | 10,323 | Form 4 |
| 2026-07-22 | Samad SamExecutive Vice President & CFO | Grant or award A | +102 | 206.81 | 33,478 | Form 4 |
| 2026-07-22 | Main Timothy LDirector | Small acquisition L | +21 | 206.81 | 22,460 | Form 4 |
| 2026-07-22 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +46 | 206.81 | 15,293 | Form 4 |
| 2026-07-22 | Gregg Vicky BDirector | Grant or award A | +72 | 206.81 | 18,386 | Form 4 |
| 2026-07-22 | Carter Robert BDirector | Small acquisition L | +11 | 206.80 | 3,864 | Form 4 |
| 2026-07-22 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +37 | 206.81 | 13,557 | Form 4 |
| 2026-06-04 | Kuppusamy KarthikSVP, Clinical Solutions | Option exercise M | +3,320 | 127.73 | 16,830 | Form 4 |
| 2026-06-04 | Kuppusamy KarthikSVP, Clinical Solutions | Option exercise M | +4,827 | 121.81 | 21,657 | Form 4 |
| 2026-05-20 | Pfeiffer Gary MDirector | Grant or award A | +1,142 | – | 31,005 | Form 4 |
| 2026-05-20 | Main Timothy LDirector | Grant or award A | +1,142 | – | 27,439 | Form 4 |
| 2026-05-20 | Carter Robert BDirector | Grant or award A | +1,142 | – | 3,853 | Form 4 |
| 2026-05-20 | Ring Timothy MDirector | Grant or award A | +1,142 | – | 31,140 | Form 4 |
| 2026-05-20 | Morrison Denise MDirector | Grant or award A | +1,142 | – | 11,929 | Form 4 |
| 2026-05-20 | Wentworth Timothy CDirector | Grant or award A | +1,142 | – | 1,358 | Form 4 |
| 2026-05-20 | Gregg Vicky BDirector | Grant or award A | +1,142 | – | 18,314 | Form 4 |
| 2026-05-20 | Doi TraceyDirector | Grant or award A | +1,142 | – | 7,748 | Form 4 |
| 2026-05-20 | Diaz LuisDirector | Grant or award A | +1,142 | – | 5,196 | Form 4 |
| 2026-05-20 | Lassiter Wright IIIDirector | Grant or award A | +1,142 | – | 10,317 | Form 4 |
| 2026-04-20 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +37 | 194.70 | 11,901 | Form 4 |
| 2026-04-20 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +39 | 194.70 | 13,490 | Form 4 |
| 2026-04-20 | Lassiter Wright IIIDirector | Small acquisition L | +6 | 194.70 | 9,063 | Form 4 |
| 2026-04-20 | Carter Robert BDirector | Small acquisition L | +7 | 194.70 | 2,711 | Form 4 |
| 2026-04-20 | Gregg Vicky BDirector | Grant or award A | +68 | 194.70 | 17,172 | Form 4 |
| 2026-04-20 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +49 | 194.70 | 15,247 | Form 4 |
| 2026-04-20 | Samad SamExecutive Vice President & CFO | Grant or award A | +108 | 194.70 | 33,376 | Form 4 |
| 2026-03-09 | Wentworth Timothy CDirector | Grant or award A | +215 | – | 215 | Form 4 |
| 2026-03-04 | Kuppusamy KarthikSVP, Clinical Solutions | Grant or award A | +6,200 | 204.86 | 16,069 | Form 4 |
| 2026-03-04 | Deppe Michael JSVP, Corp. Controller & CAO | Grant or award A | +1,473 | 204.86 | 35,946 | Form 4 |
| 2026-03-04 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −750 | 204.86 | 35,196 | Form 4 |
| 2026-03-04 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +5,682 | 204.86 | 20,880 | Form 4 |
| 2026-03-04 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −2,827 | 204.86 | 18,053 | Form 4 |
| 2026-03-04 | Davis J. E.Director, CEO and President | Grant or award A | +51,652 | 204.86 | 168,837 | Form 4 |
| 2026-03-04 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −26,414 | 204.86 | 142,423 | Form 4 |
| 2026-03-04 | Prevoznik Michael eSVP & General Counsel | Grant or award A | +7,232 | 204.86 | 44,789 | Form 4 |
| 2026-03-04 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −3,354 | 204.86 | 41,435 | Form 4 |
| 2026-03-04 | Delaney Mark eSVP & Chief Commercial Officer | Grant or award A | +5,682 | 204.86 | 14,190 | Form 4 |
| 2026-03-04 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −2,326 | 204.86 | 11,864 | Form 4 |
| 2026-03-04 | Doherty Catherine T.EVP, Regional Businesses | Grant or award A | +11,364 | 204.86 | 78,486 | Form 4 |
| 2026-03-04 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −5,806 | 204.86 | 72,680 | Form 4 |
| 2026-03-04 | Samad SamExecutive Vice President & CFO | Grant or award A | +13,947 | 204.86 | 40,988 | Form 4 |
| 2026-03-04 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −7,720 | 204.86 | 33,268 | Form 4 |
| 2026-03-02 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −88 | 204.86 | 34,473 | Form 4 |
| 2026-03-02 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −188 | 204.86 | 8,508 | Form 4 |
| 2026-03-02 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −205 | 204.86 | 9,869 | Form 4 |
| 2026-03-02 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −230 | 204.86 | 15,608 | Form 4 |
| 2026-03-02 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −2,968 | 204.86 | 127,185 | Form 4 |
| 2026-03-02 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −288 | 204.86 | 38,083 | Form 4 |
| 2026-03-02 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −869 | 204.86 | 27,041 | Form 4 |
| 2026-03-02 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −648 | 204.86 | 67,754 | Form 4 |
| 2026-02-18 | Prevoznik Michael eSVP & General Counsel | Grant or award A | +2,013 | – | 40,130 | Form 4 |
| 2026-02-18 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −301 | 210.01 | 39,829 | Form 4 |
| 2026-02-18 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −347 | 206.99 | 39,482 | Form 4 |
| 2026-02-18 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +1,952 | – | 17,333 | Form 4 |
| 2026-02-18 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −244 | 210.01 | 17,089 | Form 4 |
| 2026-02-18 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −293 | 206.99 | 16,796 | Form 4 |
| 2026-02-18 | Doherty Catherine T.EVP, Regional Businesses | Grant or award A | +2,928 | – | 70,996 | Form 4 |
| 2026-02-18 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −433 | 210.01 | 70,563 | Form 4 |
| 2026-02-18 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −728 | 206.99 | 69,835 | Form 4 |
| 2026-02-18 | Davis J. E.Director, CEO and President | Grant or award A | +15,857 | – | 136,337 | Form 4 |
| 2026-02-18 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −2,396 | 210.01 | 133,941 | Form 4 |
| 2026-02-18 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −3,788 | 206.99 | 130,153 | Form 4 |
| 2026-02-18 | Samad SamExecutive Vice President & CFO | Grant or award A | +3,965 | – | 29,706 | Form 4 |
| 2026-02-18 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −855 | 210.01 | 28,851 | Form 4 |
| 2026-02-18 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −1,010 | 206.99 | 27,841 | Form 4 |
| 2026-02-18 | Deppe Michael JSVP, Corp. Controller & CAO | Grant or award A | +366 | – | 34,742 | Form 4 |
| 2026-02-18 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −83 | 210.01 | 34,659 | Form 4 |
| 2026-02-18 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −99 | 206.99 | 34,560 | Form 4 |
| 2026-02-18 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −252 | 210.01 | 8,173 | Form 4 |
| 2026-02-18 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −259 | 206.99 | 7,914 | Form 4 |
| 2026-02-18 | Kuppusamy KarthikSVP, Clinical Solutions | Grant or award A | +2,135 | – | 10,049 | Form 4 |
| 2026-02-18 | Delaney Mark eSVP & Chief Commercial Officer | Grant or award A | +1,586 | – | 9,116 | Form 4 |
| 2026-02-18 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −205 | 210.01 | 8,911 | Form 4 |
| 2026-02-18 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −230 | 206.99 | 8,681 | Form 4 |
| 2026-02-13 | Doherty Catherine T.EVP, Regional Businesses | Option exercise M | +26,165 | 112.17 | 94,233 | Form 4 |
| 2026-02-10 | Plewman PatrickSVP for Diagnostic Services | Option exercise M | +5,662 | 121.81 | 21,043 | Form 4 |
| 2026-01-28 | Lassiter Wright IIIDirector | Small acquisition L | +7 | 183.51 | 9,057 | Form 4 |
| 2026-01-28 | Carter Robert BDirector | Small acquisition L | +6 | 183.51 | 2,704 | Form 4 |
| 2026-01-28 | Gregg Vicky BDirector | Small acquisition L | +67 | 183.51 | 17,104 | Form 4 |
| 2026-01-28 | Samad SamExecutive Vice President & CFO | Grant or award A | +69 | 183.51 | 27,910 | Form 4 |
| 2026-01-28 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +16 | 183.52 | 10,065 | Form 4 |
| 2026-01-28 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +15 | 183.51 | 8,696 | Form 4 |
| 2026-01-28 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +48 | 183.51 | 15,381 | Form 4 |
| 2025-11-25 | Davis J. E.Director, CEO and President | Option exercise M | +55,093 | 95.80 | 175,573 | Form 4 |
| 2025-11-18 | Delaney Mark eSVP & Chief Commercial Officer | Option exercise M | +7,846 | 144.47 | 15,376 | Form 4 |
| 2025-11-18 | Delaney Mark eSVP & Chief Commercial Officer | Option exercise M | +100 | 143.33 | 15,476 | Form 4 |
| 2025-11-05 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −7,143 | 175.57 | 120,480 | Form 4 |
| 2025-10-21 | Carter Robert BDirector | Grant or award A | +6 | 189.09 | 2,698 | Form 4 |
| 2025-10-21 | Delaney Mark eSVP & Chief Commercial Officer | Grant or award A | +15 | 189.08 | 7,530 | Form 4 |
| 2025-10-21 | Gregg Vicky BDirector | Grant or award A | +70 | 189.08 | 18,287 | Form 4 |
| 2025-10-21 | Kuppusamy KarthikSVP, Clinical Solutions | Grant or award A | +15 | 189.08 | 8,379 | Form 4 |
| 2025-10-21 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +46 | 189.08 | 15,333 | Form 4 |
| 2025-10-21 | Samad SamExecutive Vice President & CFO | Grant or award A | +68 | 189.08 | 25,741 | Form 4 |
| 2025-09-26 | Prevoznik Michael eSVP & General Counsel | Option exercise M | +227 | 103.57 | 38,344 | Form 4 |
| 2025-09-24 | Prevoznik Michael eSVP & General Counsel | Option exercise M | +175 | 103.57 | 38,292 | Form 4 |
| 2025-09-23 | Prevoznik Michael eSVP & General Counsel | Option exercise M | +28,288 | 103.57 | 66,405 | Form 4 |
| 2025-08-19 | Plewman PatrickSVP for Diagnostic Services | Option exercise M | +4,532 | 112.17 | 21,776 | Form 4 |
| 2025-08-13 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −123 | 175.91 | 8,338 | Form 4 |
| 2025-08-06 | Plewman PatrickSVP for Diagnostic Services | Option exercise M | +3,560 | 86.63 | 24,745 | Form 4 |
| 2025-07-30 | Kuppusamy KarthikSVP, Clinical Solutions | Option exercise M | +3,045 | 86.63 | 13,705 | Form 4 |
| 2025-07-30 | Kuppusamy KarthikSVP, Clinical Solutions | Option exercise M | +5,224 | 112.17 | 15,884 | Form 4 |
| 2025-07-21 | Carter Robert BDirector | Small acquisition L | +7 | 167.51 | 2,692 | Form 4 |
| 2025-07-21 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +17 | 167.49 | 7,515 | Form 4 |
| 2025-07-21 | Gregg Vicky BDirector | Small acquisition L | +79 | 167.50 | 18,217 | Form 4 |
| 2025-07-21 | Lassiter Wright IIIDirector | Small acquisition L | +7 | 167.51 | 9,044 | Form 4 |
| 2025-07-21 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +27 | 167.50 | 10,660 | Form 4 |
| 2025-07-21 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +80 | 167.49 | 21,185 | Form 4 |
| 2025-07-21 | Samad SamExecutive Vice President & CFO | Small acquisition L | +72 | 167.50 | 25,673 | Form 4 |
| 2025-07-16 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −850 | 169.01 | 25,601 | Form 4 |
| 2025-05-15 | Pfeiffer Gary MDirector | Grant or award A | +1,203 | – | 30,669 | Form 4 |
| 2025-05-15 | Ring Timothy MDirector | Grant or award A | +1,203 | – | 29,507 | Form 4 |
| 2025-05-15 | Lassiter Wright IIIDirector | Grant or award A | +1,203 | – | 9,037 | Form 4 |
| 2025-05-15 | Morrison Denise MDirector | Grant or award A | +1,203 | – | 10,742 | Form 4 |
| 2025-05-15 | Main Timothy LDirector | Grant or award A | +1,203 | – | 26,297 | Form 4 |
| 2025-05-15 | Doi TraceyDirector | Grant or award A | +1,203 | – | 6,490 | Form 4 |
| 2025-05-15 | Gregg Vicky BDirector | Grant or award A | +1,203 | – | 18,138 | Form 4 |
| 2025-05-15 | Diaz LuisDirector | Grant or award A | +1,203 | – | 4,054 | Form 4 |
| 2025-05-15 | Carter Robert BDirector | Grant or award A | +1,203 | – | 2,685 | Form 4 |
| 2025-04-21 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +25 | 164.42 | 9,246 | Form 4 |
| 2025-04-21 | Gregg Vicky BDirector | Grant or award A | +68 | 164.42 | 16,935 | Form 4 |
| 2025-04-21 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +81 | 164.42 | 21,087 | Form 4 |
| 2025-04-21 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +27 | 164.42 | 10,612 | Form 4 |
| 2025-04-21 | Samad SamExecutive Vice President & CFO | Small acquisition L | +74 | 164.42 | 26,451 | Form 4 |
| 2025-03-26 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −256 | 166.71 | 9,221 | Form 4 |
| 2025-03-26 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −162 | 166.71 | 20,988 | Form 4 |
| 2025-03-04 | Samad SamExecutive Vice President & CFO | Grant or award A | +13,884 | 173.74 | 34,061 | Form 4 |
| 2025-03-04 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −7,684 | 173.74 | 26,377 | Form 4 |
| 2025-03-04 | Delaney Mark eSVP & Chief Commercial Officer | Grant or award A | +5,317 | 173.74 | 11,300 | Form 4 |
| 2025-03-04 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −1,823 | 173.74 | 9,477 | Form 4 |
| 2025-03-04 | Prevoznik Michael eSVP & General Counsel | Grant or award A | +8,549 | 173.74 | 46,666 | Form 4 |
| 2025-03-04 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −3,906 | 173.74 | 42,760 | Form 4 |
| 2025-03-04 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +5,674 | 173.74 | 23,430 | Form 4 |
| 2025-03-04 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −2,280 | 173.74 | 21,150 | Form 4 |
| 2025-03-04 | Kuppusamy KarthikSVP, Clinical Solutions | Grant or award A | +4,434 | 173.74 | 14,998 | Form 4 |
| 2025-03-04 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −1,879 | 173.74 | 13,119 | Form 4 |
| 2025-03-04 | Davis J. E.Director, CEO and President | Grant or award A | +61,917 | 173.74 | 198,470 | Form 4 |
| 2025-03-04 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −31,656 | 173.74 | 166,814 | Form 4 |
| 2025-03-04 | Doherty Catherine T.EVP, Regional Businesses | Grant or award A | +10,380 | 173.74 | 78,448 | Form 4 |
| 2025-03-04 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −5,010 | 173.74 | 73,438 | Form 4 |
| 2025-03-04 | Deppe Michael JSVP, Corp. Controller & CAO | Grant or award A | +1,711 | 173.74 | 35,232 | Form 4 |
| 2025-03-04 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −867 | 173.74 | 34,365 | Form 4 |
| 2025-03-03 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −322 | 173.74 | 38,709 | Form 4 |
| 2025-03-03 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −106 | 173.74 | 17,756 | Form 4 |
| 2025-03-03 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −992 | 173.74 | 10,564 | Form 4 |
| 2025-03-03 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −1,662 | 173.74 | 136,553 | Form 4 |
| 2025-03-03 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −394 | 173.74 | 68,784 | Form 4 |
| 2025-03-03 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −1,692 | 173.74 | 33,521 | Form 4 |
| 2025-02-26 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −214 | 171.75 | 5,983 | Form 4 |
| 2025-02-26 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −88 | 171.75 | 35,212 | Form 4 |
| 2025-02-26 | Doherty Catherine T.EVP, Regional Businesses | Shares withheld for tax F | −455 | 171.75 | 70,002 | Form 4 |
| 2025-02-26 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −233 | 171.75 | 11,546 | Form 4 |
| 2025-02-26 | Plewman PatrickSVP for Diagnostic Services | Shares withheld for tax F | −229 | 171.75 | 17,853 | Form 4 |
| 2025-02-26 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −286 | 171.75 | 39,559 | Form 4 |
| 2025-02-26 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −2,966 | 171.75 | 138,215 | Form 4 |
| 2025-02-26 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −869 | 171.75 | 20,177 | Form 4 |
| 2025-02-19 | Davis J. E.Director, CEO and President | Shares withheld for tax F | −2,936 | 169.71 | 141,181 | Form 4 |
| 2025-02-19 | Delaney Mark eSVP & Chief Commercial Officer | Shares withheld for tax F | −242 | 169.71 | 6,197 | Form 4 |
| 2025-02-19 | Deppe Michael JSVP, Corp. Controller & CAO | Shares withheld for tax F | −99 | 169.71 | 35,300 | Form 4 |
| 2025-02-19 | Kuppusamy KarthikSVP, Clinical Solutions | Shares withheld for tax F | −287 | 169.71 | 11,779 | Form 4 |
| 2025-02-19 | Prevoznik Michael eSVP & General Counsel | Shares withheld for tax F | −374 | 169.71 | 40,449 | Form 4 |
| 2025-02-19 | Samad SamExecutive Vice President & CFO | Shares withheld for tax F | −1,031 | 169.71 | 21,046 | Form 4 |
| 2025-02-12 | Deppe Michael JSVP, Corp. Controller & CAO | Grant or award A | +454 | – | 35,399 | Form 4 |
| 2025-02-12 | Delaney Mark eSVP & Chief Commercial Officer | Grant or award A | +1,815 | – | 6,439 | Form 4 |
| 2025-02-12 | Doherty Catherine T.EVP, Regional Businesses | Grant or award A | +3,479 | – | 71,891 | Form 4 |
| 2025-02-12 | Kuppusamy KarthikSVP, Clinical Solutions | Grant or award A | +2,269 | – | 12,066 | Form 4 |
| 2025-02-12 | Plewman PatrickSVP for Diagnostic Services | Grant or award A | +2,042 | – | 18,402 | Form 4 |
| 2025-02-12 | Prevoznik Michael eSVP & General Counsel | Grant or award A | +2,345 | – | 40,823 | Form 4 |
| 2025-02-12 | Samad SamExecutive Vice President & CFO | Grant or award A | +4,538 | – | 22,077 | Form 4 |
| 2025-02-12 | Davis J. E.Director, CEO and President | Grant or award A | +18,149 | – | 144,117 | Form 4 |
| 2025-01-29 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +4 | 158.03 | 5,027 | Form 4 |
| 2025-01-29 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +12 | 158.03 | 9,780 | Form 4 |
| 2025-01-29 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +57 | 158.04 | 16,345 | Form 4 |
| 2025-01-29 | Samad SamExecutive Vice President & CFO | Small acquisition L | +35 | 158.04 | 17,539 | Form 4 |
| 2025-01-29 | Gregg Vicky BDirector | Small acquisition L | +72 | 158.04 | 18,117 | Form 4 |
| 2024-11-29 | Prevoznik Michael eSVP & General Counsel | Option exercise M | +35,146 | 86.63 | 73,624 | Form 4 |
| 2024-11-27 | Doherty Catherine T.EVP, Regional Businesses | Option exercise M | +33,103 | 103.57 | 101,515 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Option exercise M | +8,635 | 71.17 | 43,576 | Form 4 |
| 2024-11-06 | Deppe Michael JSVP, Corp. Controller & CAO | Option exercise M | +10,120 | 66.51 | 53,696 | Form 4 |
| 2024-10-21 | Plewman PatrickSVP for Diagnostic Services | Small acquisition L | +60 | 149.37 | 16,258 | Form 4 |
| 2024-10-21 | Kuppusamy KarthikSVP, Clinical Solutions | Small acquisition L | +21 | 149.37 | 11,509 | Form 4 |
| 2024-10-21 | Samad SamExecutive Vice President & CFO | Small acquisition L | +37 | 149.37 | 17,504 | Form 4 |
| 2024-10-21 | Delaney Mark eSVP & Chief Commercial Officer | Small acquisition L | +4 | 149.39 | 5,023 | Form 4 |
| 2024-10-21 | Gregg Vicky BDirector | Small acquisition L | +76 | 149.37 | 18,045 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.